LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

Search

Alnylam Pharmaceuticals Inc

Geschlossen

Branche Gesundheitswesen

153.9 -2

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

152.21

Max

157.22

Schlüsselkennzahlen

By Trading Economics

Einkommen

72M

-66M

Verkäufe

55M

494M

EPS

-0.16

Gewinnspanne

-13.338

Angestellte

2,100

EBITDA

100M

-2.8M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+43.04 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.6B

20B

Vorheriger Eröffnungskurs

155.9

Vorheriger Schlusskurs

153.9

Nachrichtenstimmung

By Acuity

50%

50%

124 / 370 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Alnylam Pharmaceuticals Inc Chart

Ähnliche Nachrichten

18. Juni 2024, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia in Deal to Buy Software Startup Shoreline.io, Bloomberg Reports

18. Juni 2024, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Circle K, Global Partners Sell Dozens of U.S. Stores -- OPIS

18. Juni 2024, 21:36 UTC

Market Talk

Fitch Affirms Canadian Bank Ratings, Citing Pending BOC Rate Cuts -- Market Talk

18. Juni 2024, 20:59 UTC

Top News

Exxon Lawsuit Against Activist Shareholders Thrown Out -- WSJ

18. Juni 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18. Juni 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Juni 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Juni 2024, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover -- IBD

18. Juni 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juni 2024, 19:59 UTC

Market Talk

Canada Finance Officials Aware of 'Rebalancing' in Labor Market -- Market Talk

18. Juni 2024, 19:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Juni 2024, 19:43 UTC

Market Talk

Gold Stays Elevated as Central Banks Continue To Buy -- Market Talk

18. Juni 2024, 19:17 UTC

Ergebnisse

Investors Shrugged Off Zyn's Latest Trouble. Nicotine Pouches Still Aren't in the Clear. -- Barrons.com

18. Juni 2024, 19:07 UTC

Market Talk

Oil Futures Advance as Traders Bet on Seasonal Demand -- Market Talk

18. Juni 2024, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

18. Juni 2024, 18:00 UTC

Top News

Amazon Fined by California for Failure to Disclose Worker Quotas -- WSJ

18. Juni 2024, 17:17 UTC

Market Talk

Brazil's Central Bank Expected To Pause Easing -- Market Talk

18. Juni 2024, 17:12 UTC

Market Talk

U.S. Home Prices Rise At Slowest Rate in Nearly 18 Months -- Market Talk

18. Juni 2024, 17:00 UTC

Ergebnisse

Kroger Earnings Due As Grocery Archrivals Walmart, Costco Snatch All-Time Highs -- IBD

18. Juni 2024, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

18. Juni 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Juni 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Juni 2024, 15:59 UTC

Akquisitionen, Fusionen, Übernahmen

Citi Stock Gains as Bank Showcases an Overlooked Business -- Barrons.com

18. Juni 2024, 15:37 UTC

Market Talk

Oil Gains on Expectations of Tighter Market Over Summer -- Market Talk

18. Juni 2024, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Juni 2024, 15:35 UTC

Market Talk

German Economic Sentiment Has Plateaued, But Recovery Still on Track -- Market Talk

18. Juni 2024, 15:32 UTC

Market Talk

Some Steam Expected to Come Out of Gold Price as Rates Fall -- Market Talk

18. Juni 2024, 15:28 UTC

Market Talk

German Economic Sentiment Shrugs off Political Uncertainty -- Market Talk

18. Juni 2024, 15:00 UTC

Market Talk

Kering Will Continue to Face Challenges -- Market Talk

18. Juni 2024, 14:51 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Proxy ISS Supports BBVA's Bid for Sabadell -- Market Talk

Peer-Vergleich

Kursveränderung

Alnylam Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

43.04% Vorteil

12-Monats-Prognose

Durchschnitt 225 USD  43.04%

Hoch 400 USD

Tief 138 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alnylam Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

16 ratings

11

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

153.05 / 160.05Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

124 / 370 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.